olatorepatide

**Olatorepatide (HS-20094)** is a synthetic peptide dual agonist of the glucagon-like peptide 1 receptor (**GLP-1R**) and gastric inhibitory polypeptide receptor (**GIPR**), developed by **Jiangsu Hansoh Pharmaceutical Co., Ltd.** (Hansoh Pharma). Administered as a once-weekly subcutaneous injection, it promotes insulin secretion, slows gastric emptying, suppresses appetite, and reduces food intake, leading to glycemic control, weight loss, and metabolic improvements. Phase 2 trials in type 2 diabetes mellitus (**T2DM**) patients showed dose-dependent reductions in HbA1c, fasting glucose, and body weight (up to 4.8% at 15 mg), with good tolerability and primarily mild gastrointestinal adverse events; it outperformed placebo and showed advantages over semaglutide 1 mg in some measures. **Regeneron** in-licensed ex-China rights in 2025 for $80M upfront plus up to $1.93B milestones and low double-digit royalties.[1][2][3][6]

Other names

olatorepatide